CELU$1.24
Chart
Performance
Key Stats
AI CELU Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralCelularity Inc. operates in the promising regenerative medicine sector, showing some revenue growth and positive cash flow from financing activities. However, the company is currently unprofitable, has negative free cash flow, and its stock exhibits significant volatility. Investors should approach with caution, focusing on its long-term potential in cellular therapies.
Thematic
Celularity is positioned in the high-growth regenerative medicine and cellular therapies market, addressing aging-related and degenerative diseases. The demand for such therapies is expected to increase, but the sector is capital-intensive and faces regulatory hurdles.
Fundamental
Celularity is in an early stage of development with significant losses and negative free cash flow. While revenue has shown growth, profitability remains elusive. The company's financial position indicates a need for continued funding.
Technical
The stock has experienced significant price declines over the past year but has shown some recovery in recent months. Technical indicators suggest a mixed outlook, with potential for further volatility.
| Factor | Score |
|---|---|
| Regenerative Medicine Growth | 85 |
| Cellular Therapy Innovation | 75 |
| Biopharma Partnerships | 65 |
| Regulatory Landscape | 50 |
| Aging Population Demographics | 80 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 65 |
| Balance Sheet Health | 20 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 55 |
| Moving Averages | 45 |
| Volume | 50 |
| Price Action | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Focus on Regenerative Medicine
Celularity Inc. operates in the regenerative and cellular medicines sector, focusing on treatments for aging-related and degenerative diseases. Their approach utilizes placental-derived allogeneic cell therapy product candidates. The company has a diversified business model spanning Cell Therapy, Degenerative Disease, and BioBanking, and holds licensing agreements with entities like Sorrento Therapeutics and research collaborations with Regeneron Pharmaceuticals.
Short-Term Positive Momentum
The stock has shown strong performance over shorter periods, with a 60.0% return in the last month and a 21.31% return in the last six months. Year-to-date, the performance is 34.55%.
Bearish Points (9)
Consistent Net Losses
Celularity Inc. has consistently reported net losses across all reported periods. The Net Income for 2024Q4 was -$57.892 million, with a Net Margin of -106.8%. This indicates the company is not currently profitable and is consuming cash.
Negative and Volatile EPS
Reported EPS figures are consistently negative and show significant variance from estimates. For example, in Q1 2024, reported EPS was -0.50 compared to an estimate of -0.03, a substantial miss. This indicates a lack of earnings predictability and consistent underperformance against expectations.
Calendar
July 2025
31
Next Earnings Date
H: $
A: $
L: $
Profile
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Seasonals
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor developing allogeneic CAR T-cell therapies for various cancers, a key focus area for Celularity's placental-derived CAR T programs.
Weight: 95
Direct competitor focused on developing allogeneic NK cell therapies, similar to Celularity's lead CYNK-001 program based on placental-derived NK cells.
Weight: 92
Developing iPSC-derived allogeneic NK and T-cell immunotherapies, a direct competitor in the 'off-the-shelf' cell therapy space with similar therapeutic modalities.
Weight: 90
Specializes in iPSC-derived allogeneic cell therapies for cancer, directly competing with Celularity's allogeneic cell therapy development strategy.